Therapeutic Innovation Australia (TIA), in partnership with Phenomics Australia, Bioplatforms Australia and ANSTO’s National Deuteration Facility, is thrilled to announce the successful recipients of the Pipeline Accelerator 2024-25 (Round 2).
Enabled by the National Collaborative Research Infrastructure Strategy (NCRIS), all four NCRIS providers mentioned above are working together to help address the medical products challenge outlined in the 2021 National Research Infrastructure (NRI) Roadmap. Together, they provide academic researchers and SMEs seamless access to world-class Australian translational research infrastructure, spanning the molecular basis of health and disease through to clinical trials.
This round, 40 projects, including one Technical Feasibility Assessment (TFA), will share a total of $1,324,362 in voucher awards with a total cash co-investment fund of $1,745,302. These vouchers will subsidise the cost to access these translation NRIs to accelerate therapeutic translation and improve human health including, but not limited to, diabetes, heart disease, pain relief, cancer therapy, neurological disorders and women’s health.
We’re pleased to welcome Bioplatforms Australia to the scheme as a provider of supplementary vouchers. This round, five researchers have been awarded vouchers to access facilities supported by TIA or Phenomics Australia, along with additional vouchers enabling access to Bioplatforms Australia’s capabilities.
- Dr Rudrarup Bhattacharjee (University of Adelaide) – Functional Genomics South Australia (TIA) and Monash Proteomics & Metabolomics Platform (Bioplatforms Australia)
- Dr Steve Dingwall (University of Queensland) – Protein Expression Facility (TIA) and Metabolomics Australia (Bioplatforms Australia)
- Dr Zhi Ying Kho (Monash University) – National Drug Discovery Centre (TIA) and Monash Proteomics & Metabolomics Platform (Bioplatforms Australia)
- Prof Claudia Nold (Hudson Institute of Medical Research) – Monash Organoid Program (Phenomics Australia) and Monash Proteomics and Metabolomics Platform (Bioplatforms Australia)
- Dr Tan Nguyen (Walter Eliza Hall Institute/ exteRNA) – Monash Functional Genomics Platform (Phenomics Australia) and Drug Target Identification Platform (Bioplatforms Australia)
Click here to see the Phenomics Australia voucher recipients.
The full list of awardees for the TIA Pipeline Accelerator and Technical Feasibility Assessment 2024-25 (Round 2) can be found below: https://therapeuticinnovation.com.au/pipeline-accelerator-2024-25-round-2-outcomes/